RxDoctor Payments Data

Stephen Feuerborn, MD

Family Medicine · Seminole, OKNPI 1760441612

Payments from drug & device makers

$455in general payments, 2019–2025

Across 28 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$173
  • Lilly USA, LLC$110
  • Sumitomo Pharma America, Inc.$50
  • Pfizer$20
  • AstraZeneca$18
  • Amgen$16
  • plus $66 from 5 others

What the payments were for

  • Food & beverage$455100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)10$173
Lilly USA, LLC7$110
Sumitomo Pharma America, Inc.3$50
Pfizer1$20
AstraZeneca1$18
Amgen1$16
Exact Sciences1$15
GSK1$14
Dexcom, Inc.1$14
Merck1$12
Novartis1$11

How this compares

$455 in reported general payments places this provider in the 50th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$81,822
Medicare patients
283
Services billed
1,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$76,267
EliquisApixaban95$72,985
TrulicityDulaglutide56$64,594
JanuviaSitagliptin Phosphate42$53,447
JardianceEmpagliflozin21$31,319
MyrbetriqMirabegron54$27,978
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$25,651
MounjaroTirzepatide19$25,631
TradjentaLinagliptin13$20,999
FarxigaDapagliflozin Propanediol12$20,917
Tresiba Flextouch U-200Insulin Degludec11$15,648
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog38$14,554
AptiomEslicarbazepine Acetate11$14,258
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr24$12,881
Spiriva HandihalerTiotropium Bromide16$10,127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$110$90,22575 claims
PfizerEliquis$20$72,98595 claims
MerckJanuvia$12$53,44742 claims
GSKTrelegy Ellipta, Anoro Ellipta$14$38,53346 claims
AstraZenecaFarxiga$18$20,91712 claims
NovartisEntresto$11$7,20020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Seminole

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →